At the time of writing, Monopar Therapeutics Inc [MNPR] stock is trading at $68.77, down -2.84%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The MNPR shares have gain 4.21% over the last week, with a monthly amount drifted -22.27%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Monopar Therapeutics Inc [NASDAQ: MNPR] stock has seen the most recent analyst activity on November 14, 2025, when Raymond James downgraded its rating to an Outperform. Previously, Leerink Partners started tracking the stock with Outperform rating on November 10, 2025, and set its price target to $115. On October 13, 2025, Barclays initiated with an Overweight rating and assigned a price target of $125 on the stock. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $87 on September 09, 2025. Raymond James initiated its recommendation with a Strong Buy and recommended $80 as its price target on September 03, 2025. Oppenheimer started tracking with an Outperform rating for this stock on September 03, 2025, and assigned it a price target of $77.
For the past year, the stock price of Monopar Therapeutics Inc fluctuated between $21.00 and $105.00. Currently, Wall Street analysts expect the stock to reach $107.43 within the next 12 months. Monopar Therapeutics Inc [NASDAQ: MNPR] shares were valued at $68.77 at the most recent close of the market. An investor can expect a potential return of 56.22% based on the average MNPR price forecast.
Analyzing the MNPR fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.02, Equity is -0.1 and Total Capital is -0.03. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 66.84 points at the first support level, and at 64.92 for the second support level. However, for the 1st resistance point, the stock is sitting at 71.47, and for the 2nd resistance point, it is at 74.17.
Ratios To Look Out For
It is important to note that Monopar Therapeutics Inc [NASDAQ:MNPR] has a current ratio of 56.10. Further, the Quick Ratio stands at 56.10, while the Cash Ratio is 49.71.
Transactions by insiders
Recent insider trading involved Arthur Klausner, Board Member, that happened on Dec 18 ’25 when 5121.0 shares were purchased. Director, KLAUSNER ARTHUR J completed a deal on Dec 18 ’25 to sell 5121.0 shares. Meanwhile, 10% Owner Tactic Pharma LLC sold 0.55 million shares on Sep 24 ’25.
